Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer

Karine Pozo, Stefan Zahler, Keisuke Ishimatsu, Angela M. Carter, Rahul Telange, Chunfeng Tan, Shuaijun Wang, Roswitha Pfragner, Junya Fujimoto, Elizabeth Gardner Grubbs, Masaya Takahashi, Sarah C. Oltmann, James A Bibb

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Medullary thyroid carcinoma (MTC) is a slow growing neuroendocrine (NE) tumor for which few treatment options are available. Its incidence is rising and mortality rates have remained unchanged for decades. Increasing the repertoire of available treatments is thus crucial to manage MTC progression. Scarcity of patient samples and of relevant animal models are two challenges that have limited the development of effective non-surgical treatments. Here we use a clinically accurate mouse model of MTC to assess the effects and mode of action of the tyrosine kinase inhibitor (TKI) Vandetanib, one of only two drugs currently available to treat MTC. Effects on tumor progression, histopathology, and tumorigenic signaling were evaluated. Vandetanib blocked MTC growth through an anti-angiogenic mechanism. Furthermore, Vandetanib had an apparent anti-angiogenic effect in a patient MTC sample. Vandetanib displayed minimal anti-proliferative effects in vivo and in human and mouse MTC tumor-derived cells. Based on these results, we evaluated the second-generation TKI, Nintedanib, alone and in combination with the histone deacetylase (HDAC) inhibitor, Romidepsin, as potential alternative treatments to Vandetanib. Nintedanib showed an anti-angiogenic effect while Romidepsin decreased proliferation. Mechanistically, TKIs attenuated RET-, VEGFR2- and PI3K/AKT/FOXO signaling cascades. Nintedanib alone or in combination with Romidepsin, but not Vandetanib, inhibited mTOR signaling suggesting Nintedanib may have broader anti-cancer applicability. These findings validate the MTC mouse model as a clinically relevant platform for preclinical drug testing and reveal the modes of action and limitations of TKI therapies.

Original languageEnglish (US)
Pages (from-to)37662-37675
Number of pages14
JournalOncotarget
Volume9
Issue number102
StatePublished - Dec 1 2018

Fingerprint

Thyroid Neoplasms
Protein-Tyrosine Kinases
Therapeutics
Neoplasms
Histone Deacetylase Inhibitors
Neuroendocrine Tumors
Medullary Thyroid cancer
Phosphatidylinositol 3-Kinases
Pharmaceutical Preparations
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
Animal Models
Mortality
nintedanib
Incidence
Growth
romidepsin

Keywords

  • Animal model
  • Medullary thyroid carcinoma
  • Targeted therapy
  • Tyrosine kinase inhibitors
  • Vandetanib

ASJC Scopus subject areas

  • Oncology

Cite this

Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer. / Pozo, Karine; Zahler, Stefan; Ishimatsu, Keisuke; Carter, Angela M.; Telange, Rahul; Tan, Chunfeng; Wang, Shuaijun; Pfragner, Roswitha; Fujimoto, Junya; Grubbs, Elizabeth Gardner; Takahashi, Masaya; Oltmann, Sarah C.; Bibb, James A.

In: Oncotarget, Vol. 9, No. 102, 01.12.2018, p. 37662-37675.

Research output: Contribution to journalArticle

Pozo, K, Zahler, S, Ishimatsu, K, Carter, AM, Telange, R, Tan, C, Wang, S, Pfragner, R, Fujimoto, J, Grubbs, EG, Takahashi, M, Oltmann, SC & Bibb, JA 2018, 'Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer', Oncotarget, vol. 9, no. 102, pp. 37662-37675.
Pozo K, Zahler S, Ishimatsu K, Carter AM, Telange R, Tan C et al. Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer. Oncotarget. 2018 Dec 1;9(102):37662-37675.
Pozo, Karine ; Zahler, Stefan ; Ishimatsu, Keisuke ; Carter, Angela M. ; Telange, Rahul ; Tan, Chunfeng ; Wang, Shuaijun ; Pfragner, Roswitha ; Fujimoto, Junya ; Grubbs, Elizabeth Gardner ; Takahashi, Masaya ; Oltmann, Sarah C. ; Bibb, James A. / Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer. In: Oncotarget. 2018 ; Vol. 9, No. 102. pp. 37662-37675.
@article{b37d2644b24b4d69938cd33a256f1dfe,
title = "Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer",
abstract = "Medullary thyroid carcinoma (MTC) is a slow growing neuroendocrine (NE) tumor for which few treatment options are available. Its incidence is rising and mortality rates have remained unchanged for decades. Increasing the repertoire of available treatments is thus crucial to manage MTC progression. Scarcity of patient samples and of relevant animal models are two challenges that have limited the development of effective non-surgical treatments. Here we use a clinically accurate mouse model of MTC to assess the effects and mode of action of the tyrosine kinase inhibitor (TKI) Vandetanib, one of only two drugs currently available to treat MTC. Effects on tumor progression, histopathology, and tumorigenic signaling were evaluated. Vandetanib blocked MTC growth through an anti-angiogenic mechanism. Furthermore, Vandetanib had an apparent anti-angiogenic effect in a patient MTC sample. Vandetanib displayed minimal anti-proliferative effects in vivo and in human and mouse MTC tumor-derived cells. Based on these results, we evaluated the second-generation TKI, Nintedanib, alone and in combination with the histone deacetylase (HDAC) inhibitor, Romidepsin, as potential alternative treatments to Vandetanib. Nintedanib showed an anti-angiogenic effect while Romidepsin decreased proliferation. Mechanistically, TKIs attenuated RET-, VEGFR2- and PI3K/AKT/FOXO signaling cascades. Nintedanib alone or in combination with Romidepsin, but not Vandetanib, inhibited mTOR signaling suggesting Nintedanib may have broader anti-cancer applicability. These findings validate the MTC mouse model as a clinically relevant platform for preclinical drug testing and reveal the modes of action and limitations of TKI therapies.",
keywords = "Animal model, Medullary thyroid carcinoma, Targeted therapy, Tyrosine kinase inhibitors, Vandetanib",
author = "Karine Pozo and Stefan Zahler and Keisuke Ishimatsu and Carter, {Angela M.} and Rahul Telange and Chunfeng Tan and Shuaijun Wang and Roswitha Pfragner and Junya Fujimoto and Grubbs, {Elizabeth Gardner} and Masaya Takahashi and Oltmann, {Sarah C.} and Bibb, {James A}",
year = "2018",
month = "12",
day = "1",
language = "English (US)",
volume = "9",
pages = "37662--37675",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "102",

}

TY - JOUR

T1 - Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer

AU - Pozo, Karine

AU - Zahler, Stefan

AU - Ishimatsu, Keisuke

AU - Carter, Angela M.

AU - Telange, Rahul

AU - Tan, Chunfeng

AU - Wang, Shuaijun

AU - Pfragner, Roswitha

AU - Fujimoto, Junya

AU - Grubbs, Elizabeth Gardner

AU - Takahashi, Masaya

AU - Oltmann, Sarah C.

AU - Bibb, James A

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Medullary thyroid carcinoma (MTC) is a slow growing neuroendocrine (NE) tumor for which few treatment options are available. Its incidence is rising and mortality rates have remained unchanged for decades. Increasing the repertoire of available treatments is thus crucial to manage MTC progression. Scarcity of patient samples and of relevant animal models are two challenges that have limited the development of effective non-surgical treatments. Here we use a clinically accurate mouse model of MTC to assess the effects and mode of action of the tyrosine kinase inhibitor (TKI) Vandetanib, one of only two drugs currently available to treat MTC. Effects on tumor progression, histopathology, and tumorigenic signaling were evaluated. Vandetanib blocked MTC growth through an anti-angiogenic mechanism. Furthermore, Vandetanib had an apparent anti-angiogenic effect in a patient MTC sample. Vandetanib displayed minimal anti-proliferative effects in vivo and in human and mouse MTC tumor-derived cells. Based on these results, we evaluated the second-generation TKI, Nintedanib, alone and in combination with the histone deacetylase (HDAC) inhibitor, Romidepsin, as potential alternative treatments to Vandetanib. Nintedanib showed an anti-angiogenic effect while Romidepsin decreased proliferation. Mechanistically, TKIs attenuated RET-, VEGFR2- and PI3K/AKT/FOXO signaling cascades. Nintedanib alone or in combination with Romidepsin, but not Vandetanib, inhibited mTOR signaling suggesting Nintedanib may have broader anti-cancer applicability. These findings validate the MTC mouse model as a clinically relevant platform for preclinical drug testing and reveal the modes of action and limitations of TKI therapies.

AB - Medullary thyroid carcinoma (MTC) is a slow growing neuroendocrine (NE) tumor for which few treatment options are available. Its incidence is rising and mortality rates have remained unchanged for decades. Increasing the repertoire of available treatments is thus crucial to manage MTC progression. Scarcity of patient samples and of relevant animal models are two challenges that have limited the development of effective non-surgical treatments. Here we use a clinically accurate mouse model of MTC to assess the effects and mode of action of the tyrosine kinase inhibitor (TKI) Vandetanib, one of only two drugs currently available to treat MTC. Effects on tumor progression, histopathology, and tumorigenic signaling were evaluated. Vandetanib blocked MTC growth through an anti-angiogenic mechanism. Furthermore, Vandetanib had an apparent anti-angiogenic effect in a patient MTC sample. Vandetanib displayed minimal anti-proliferative effects in vivo and in human and mouse MTC tumor-derived cells. Based on these results, we evaluated the second-generation TKI, Nintedanib, alone and in combination with the histone deacetylase (HDAC) inhibitor, Romidepsin, as potential alternative treatments to Vandetanib. Nintedanib showed an anti-angiogenic effect while Romidepsin decreased proliferation. Mechanistically, TKIs attenuated RET-, VEGFR2- and PI3K/AKT/FOXO signaling cascades. Nintedanib alone or in combination with Romidepsin, but not Vandetanib, inhibited mTOR signaling suggesting Nintedanib may have broader anti-cancer applicability. These findings validate the MTC mouse model as a clinically relevant platform for preclinical drug testing and reveal the modes of action and limitations of TKI therapies.

KW - Animal model

KW - Medullary thyroid carcinoma

KW - Targeted therapy

KW - Tyrosine kinase inhibitors

KW - Vandetanib

UR - http://www.scopus.com/inward/record.url?scp=85059391394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059391394&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85059391394

VL - 9

SP - 37662

EP - 37675

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 102

ER -